Genmab — April 2022
-
we need earlier lines and combination treatment and additional indications to see of it will really hit off, but it seems promising so far to me. They have the time now to figure out how to best deal with the eye problems while the indication is still small
-
did Jan say that? or
24/9 09:28
af Sukkeralf
In this Tivdak link they state that the approval come with a black box warning of ocular tox. That analyst project $300-400 million peaksales in second line for Tivdak. That the combination data seen at ESMO show promise for 1 line -
this i couldn't read https://medwatch.com/News/Pharma___Biotech/article13744402.ece
-
Valuta: Dollar i stærkeste niveau siden 2016 https://www.proinvestor.com/investornyt/816212/valuta-dollar-i-staerkeste-niveau-siden-2016
-
I am not listening to the AbbVie call, but: Amy Brown
@ByAmyBrown
$ABBV also confirms it will seek talks with FDA about accelerated application for epcoritamab, anti-CD20 bispecific from $GMAB. https://twitter.com/ByAmyBrown/status/1520033764138749952 -
Fredagens aktier: Novo dagens store vinder mens Danske Bank dykkede https://www.proinvestor.com/investornyt/816323/fredeagens-aktier-novo-dagens-store-vinder-mens-danske-bank-dykkede
-
Epco on a meeting in the very near future https://seekingalpha.com/article/4505115-abbvie-inc-abbv-ceo-rick-gonzalez-on-q1-2022-results-earnings-call-transcript
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind